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Copyright © 2010 JCBN Summary Diet-induced obesity in C57BL/6 mice triggers common features of human
metabolic syndrome (MetS). The purpose is to assess the suitability of a diet-induced obesity
model for investigating non-alcoholic fatty pancreatic disease (NAFPD), fatty liver and insulin
resistance. Adult C57BL/6 mice were fed either high-fat chow (HFC, 60% fat) or standard
chow (SC, 10% fat) during a 16-week period. We evaluated in both groups: hepatopancreatic
injuries, pancreatic islets size, alpha and beta-cell immunodensities, intraperitoneal insulin
tolerance test (IPITT) and oral glucose tolerance test (OGTT). The HFC mice displayed
greater mass gain (p<0.0001) and total visceral fat pads (p<0.001). OGTT showed impairment
of glucose clearance in HFC mice (p<0.0001). IPITT revealed insulin resistance in HFC mice
(p<0.0001). The HFC mice showed larger pancreatic islet size and significantly greater alpha
and beta-cell immunodensities than SC mice. Pancreas and liver from HFC were heavier and
contained higher fat concentration. In conclusion, C57BL/6 mice fed a high-fat diet develop
features of NAFPD. Insulin resistance and ectopic accumulation of hepatic fat are well known
to occur in MetS. Additionally, the importance of fat accumulation in the pancreas has been
recently highlighted. Therefore, this model could help to elucidate target organ alterations
associated with metabolic syndrome.
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Introduction
Obesity leads to the infiltration of fat in multiple organs
including the heart, kidneys, liver, and pancreas. When
accompanied by insulin resistance or type 2 diabetes (T2D),
hypertension and dyslipidemia significantly increase the risk
for cardiovascular disease [1]; in patients suffering from
metabolic syndrome (MetS), this risk is even greater [2].
High-fat diet (HFD) is a nutritional condition that accounts
for the largest incidence of MetS in the world [3]. A major
cause of steatosis, also known as fatty liver disease, is
increased fatty acid flux to the liver, which is promoted by a
high availability of plasma free fatty acids (FFAs) in relation
to peripheral oxidative requirements. Several conditions
increase fatty acid flux to the liver, pancreas and adipose
tissue [4–6]. Consequently, elevated insulin levels generate
oxidative stress and organ injuries [5, 7]. The pathophysio-
logical consequence of fat infiltration is an increase in
cellular FFAs and decreased beta-oxidation, ultimately
resulting in triglyceride accumulation. This accumulation
manifests as an increase in dietary FFAs and lipolysis in
peripheral fat tissue [4, 8].
In general, there is continuous cycling and redistributionExperimental Model of Metabolic Syndrome
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of non-oxidized fatty acids between different organs. An
early event in the development of obesity is an increase
in visceral adipose tissue, particularly in the size of the
white adipocytes. This transformation is seen to precede
the development of fatty liver and insulin resistance, which
are marked on a cellular level by hepatic fat infiltration
and tumor necrosis factor alpha (TNF-alpha) expression [6].
Infiltration of the liver by fat, or nonalcoholic fatty liver
disease (NAFLD), is a major form of chronic liver disease
in adults and children. NAFLD is one consequence of the
current obesity epidemic, and can progress to nonalcoholic
steatohepatitis (NASH), which is characterized by steatosis,
inflammation, and progressive fibrosis, ultimately leading
to cirrhosis and end-stage liver disease [9, 10]. Likewise,
infiltration of the pancreas by fat or NAFPD, is character-
ized by a heavier pancreas due to more pancreatic fat,
consisting of a high composition of triglycerides and FFAs,
as well as increased cytokine production [5, 11]. Pancreatic
fat accumulation can compromise normal pancreatic func-
tion. Under conditions of oxidative stress, fat-derived cyto-
kines are released locally and may result in inflammatory
processes associated with organ dysfunction. In addition,
elevated levels of circulating FFAs alone are implicated in
beta-cell dysfunction, leading to increased basal insulin
release and impaired glucose-stimulated insulin secretion by
beta-cells [12–14].
In T2D, beta-cells eventually fail to meet the demand
created by insulin resistance, leading to hyperglycemia.
However, in most of these disorders, the beta-cells compen-
sate for the insulin resistance for long periods with an increase
in secretory capacity, an increase in beta-cell mass, or both.
However, the factors that contribute to beta-cell hyperplasia
in insulin resistant states remain poorly understood [12].
In the present study, we sought to evaluate structural
adaptations in pancreas, liver and fat storage in response to
an increased dietary supply of fat using a C57BL/6 mouse
model of high-fat diet-induced insulin resistance, a model
that displays several correlations to human MetS.
Materials and Methods
Animals and diets
Eight-week-old male C57BL/6 mice were used in this
study, housed in a temperature-controlled (21 ± 2°C) room
on a 12:12 h dark-light cycle with free access to food and
water. All procedures were carried out in accordance with
conventional guidelines for experimentation with animals
(NIH Publication Nº. 85-23, revised in 1996) and experi-
mental protocols were approved by the local Committee.
Mice were separated into two groups (n = 10 for each
group) and fed different diets during a 16 week period:
high-fat chow (HFC, 26% of calories from carbohydrates,
60% from fat, and 14% from protein), or standard chow (SC,
76% of calories from carbohydrates, 10% from fat, and 14%
from protein). The mineral and vitamin content of the two
diets were identical and in accordance with the American
Institute of Nutrition’s recommendation (AIN 93M) [15]
(details in Table 1). Fresh chow was provided daily and any
chow remaining from the previous day was discarded. Food
intake was evaluated daily (1 p.m.), and body mass was
measured weekly. Caloric content of food intake was deter-
mined based on 5.404 kcal/g for high-fat and 3.573 kcal/g
for standard chow diets. The feed efficiency (FE) [(weight
gained/kcal consumed) × 100] was determined after 16 weeks
on the respective diets.
Oral glucose tolerance test (OGTT)
Fasting blood glucose was measured (6 h fast, blood taken
from the tail vein) according to manufacturers’ recommen-
dations using an Accu-Chek glucometer (Roche Diagnostics
GmbH, Mannheim, Germany). Glucose was then admin-
istrated by gavage (25% glucose solution, 1 g/kg mice) and
blood glucose was measured again at time points of 15, 30,
60 and 120 min, post gavage.
Intraperitoneal Insulin tolerance test (IPITT)
Fasting blood glucose was measured (4 h fast, blood
taken from the tail vein) using a glucosimeter (Roche
Diagnostics GmbH, Mannheim, Germany). Insulin was then
injected intraperitoneally (1 U/kg) and blood glucose was
measured again at time points of 15, 30, 60 and 120 min,
post injection.
Table 1. Composition and energy content of the standard chow
(SC) and high-fat chow (HFC).
*Mineral and vitamin mixtures.
Content (g/Kg)
Diets
SC HFC
Casein (≥85% de protein) 140 190
Cornstarch 620.7 250.7
Sucrose 100 100
Soybean oil 40 40
Lard — 320
Fiber 50 50
Vitamin mix* 10 10
Mineral mix* 35 35
L-Cystin 1.8 1.8
Choline 2.5 2.5
Antioxidant 0.008 0.008
Total grams 1,000 1,000
Energy content (Kcal/Kg) 3,573 5,404
Carbohydrates (%) 76 26
Protein (%) 14 14
Lipids (%) 10 60J.C. Fraulob et al.
J. Clin. Biochem. Nutr.
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Euthanasia
After 16 weeks on a diet, mice were deeply anesthetized
(intraperitoneal sodium pentobarbital, 45 mg/kg) and blood
samples were rapidly obtained by cardiac puncture of the
right atrium. Plasma was then obtained by centrifugation
(120 g for 15 min) at room temperature and stored indi-
vidually at −20°C until biochemical analyses were per-
formed.
Pancreas, liver and fat pads (epididymal, retroperitoneal
and perirenal fat pads) were carefully removed and weighed.
Organ masses were then analyzed relative to tibia length in
order to standardize body biometry (we used the left tibia
length for this standardization because body masses varied
within the groups; the left tibia was dissected and the dis-
tance between the condyle to the tip of the medial malleolus
was measured) [16]. Tissue was then rapidly fixed in freshly
prepared fixative solution (formaldehyde 4% w/v, 0.1 M
phosphate buffer, pH 7.2) for analysis by light microscopy.
Biochemical analysis
Total cholesterol and triglycerides (TG) were assayed
by the colorimetric enzymatic method. The high-density
lipoprotein-cholesterol (HDL-c) was measured using the
kinetic-colorimetric method, according to the manufacturer’s
instructions (Bioclin System II, Quibasa, Belo Horizonte,
MG, Brazil). The low-density lipoprotein-cholesterol
(LDL-c) was obtained via the Friedwald’s formula [17, 18].
The enzymes alanine aminotransferase (ALT), aspartate
aminotransferase (AST) and alkaline phosphatase (ALK)
were also measured.
Radioimmunoassay for insulin and costicosterone and
HOMA-IR
Plasma insulin concentrations were measured using an
insulin RIA (radioimmunoassay) kit (Linco Research, St.
Charles, MO, Cat. RI-13K) and plasma corticosterone
concentrations were measured using a corticosterone RIA kit
(Immuchem Double Antibody, MP Biomedicals, Orangeburg,
NY). All samples were analyzed in a double assay format,
for which the intra-assay coefficient of variation was 1.4%
for insulin and 4.4% for corticosterone. The HOMA-IR
(homeostasis model assessment of insulin resistance) index
was calculated as [fasting serum glucose × fasting serum
insulin/22.5] to assess insulin resistance [17].
Liver, pancreas and adipose tissue
Small pieces of liver, pancreas and epididymal fat pads
were embedded in Paraplast plus (Sigma-Aldrich, St. Louis,
MO), sectioned at 5 μm and then stained with hematoxylin-
eosin. The liver sections were observed under light micros-
copy (Olympus BX51 microscope), in order to investigate
the structure of the hepatic lobule and hepatocyte steatosis.
The pancreatic islet is nearly circular, allowing for deter-
mination of the mean islet diameter based on the greatest
and smallest diameters in the equatorial islet plane. These
measurements were made with the software Image-Pro Plus
version 5.0 (Media Cybernetics, Silver Spring, MD) with a
sample size of at least 200 islets per group (digital images
TIFF format, 36-bit color, 1280 × 1024 pixels, LC Evolution
camera and Olympus BX51 microscope).
The pancreas islet number was estimated with the physical
disector-fractionator method (for details see [19–21]). Briefly,
in a consecutive series of sections, starting with a random
section, for example number 10, and leaving an interval of
50 sections, we determined the primary sections (sections
numbers 60, 110, 160 etc.). From the intervals between
these primary sections, we separated the reference sections
(e.g. section numbers 18, 68, 118, 168, and so on) used to
quantify the total number of pancreatic islet by the physical
fractionator method. The distance between primary and
reference sections was 40 μm for each step. This represents
about 1/4 of the islet diameter in this animal. Thus, islets seen
at primary sections (e.g. section 10) but not in the reference
sections (e.g. section 18) were counted. The remaining
sections were used for immunohistochemical analysis and
observation of interlobular and intralobular fat deposits.
To estimate the cross-sectional area of adipocytes, at least
50 adipocytes per animal were measured with the software
Image-Pro Plus version 5.0 (Media Cybernetics—digital
images TIFF format, 36-bit color, 1280 × 1024 pixels, LC
Evolution camera and Olympus BX51 microscope).
Immunohistochemistry
Antigen retrieval was performed using citrate buffer
pH 6.0, and endogenous peroxidase was quenched by
hydrogen peroxide 3%. Sections were then incubated with
rabbit anti-glucagon (A0565, Dako) and guinea pig anti-
insulin (A0564, Dako) antibodies for 2 h. Subsequently,
samples were treated with a biotinylated secondary antibody
(K0679, Universal DakoCytomation LSAB + Kit, Peroxi-
dase, Glostrup, Denmark), which was detected by reaction
with horseradish peroxidase-streptavidin-biotin complex.
Positive immunoreactions were identified following incuba-
tion with 3,3' diaminobenzidine tetrachloride (K3466, DAB,
DakoCytomation) and sections were then counterstained
with Mayer hematoxylin.
Digital images of the stained slices were obtained (LC
Evolution camera, Olympus BX51 microscope, TIFF format,
36-bit color, 1280 × 1024 pixels) and analyzed with the
software Image-Pro Plus version 5.0 (Media Cybernetics).
The density threshold selection tool was used to select
the areas of the pancreatic islet marked with insulin and
glucagon, which was then expressed as a percentage of the
islet mean cross-sectional area (immuno-density). The
average of 10 islets per animal was calculated for each
group.Experimental Model of Metabolic Syndrome
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Data analysis
The data are displayed as mean and standard error of the
mean (SEM). Differences between the groups were analyzed
with the Student t test and a p value ≤0.05 was considered as
statistically significant (GraphPad Prism 5.1, GraphPad
Software, La Jolla, CA).
Results
Body mass, fat pads and adipocyte morphometry
HFC mice had greater mass gain compared to SC mice
(Fig. 1, Table 2). Significant body mass differences were
observed from the second week. At the 16th week, body
mass was more than 30% greater in HFC mice than in SC
(p = 0.002). Likewise, the fat pads were significantly larger
in HFC mice than in SC mice: total visceral fat pads
(+143%,  p = 0.003), retroperitoneal fat (+124%, p<0.01),
epididymal fat (+90%, p<0.01) (Fig. 2). The morphometry
of adipocytes showed adipocyte hypertrophy in HFC mice
when compared to SC mice (adipocyte diameter varied from
56.7 ± 0.5 μm in SC mice to 86.5± 0.9 μm in HFC mice,
+52%, p<0.0001) (Fig. 2).
Food intake and feed efficiency
Food intake was not different between the groups, but
both the energy (+38%, p<0.05) and fat intake per animal
(+729%, p<0.001) were greater in HFC mice than in SC
(Table 2). Feed efficiency (body mass gain in grams per
kilocalories consumed) was therefore greater in HFC mice
than in SC mice (Fig. 3).
Fig. 1. Body mass. Body mass evolution and respective areas under the curve (AUC) show significant differences between the body
mass gain in the standard chow (SC) group and in the very high-fat chow (HFC) group. Values are mean ± SEM, n = 10/group.
*p<0.05, different from HFC Group.
Table 2. Body composition, food and fat intakes and feed efficiency in mice fed standard chow (SC) and
high-fat chow (HFC).
Values are mean ± SEM (n = 8/group). Data were analyzed by Student’s t test.
Biometry and Nourishment data
Groups SC vs HFC
SC HFC p
Final body weight, g 25.9 ± 0.4 33.9 ± 0.7 <0.001
Body weight gain, g/week 0.3 ± 0.09 0.7 ± 0.1 0.01
Pancreas/Tibial, g/cm 0.11 ± 0.01 0.13 ± 0.01 0.03
Liver/Tibial, g/cm 0.44 ± 0.01 0.56 ± 0.01 <0.001
Total visceral fat 1.1 ± 0.4 2.7 ± 0.4 <0.001
Food intake, g/day/mice 2.4 ± 0.06 2.2 ± 0.1 ns
Energy intake, Kcal/day/mice 8.4 ± 0.2 11.9 ± 0.1 <0.001
Lipid intake, Kcal/day/mice 0.8 ± 0.02 7.1 ± 0.2 <0.001
Feed efficiency, % 0.5 ± 0.1 0.9 ± 0.1 0.01J.C. Fraulob et al.
J. Clin. Biochem. Nutr.
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Blood biochemistry
Plasma levels of TG (p = 0.001), HDL-c (p = 0.002) and
LDL-c (p = 0.02), but not total cholesterol, were higher in
HFC mice than in SC mice. Plasma ALT (p = 0.01), AST
(p<0.001) and ALK (p<0.001) concentrations were also
significantly elevated in the HFC mice when compared to
SC mice (Table 3).
Homeostasis model assessment of insulin resistance and
plasma costicosterone
Both the fasting plasma glucose (p = 0.01) and insulin
(p = 0.02) were increased in HFC mice in comparison with
SC mice. Therefore, HFC mice presented higher HOMA-IR
(p<0.001) and higher levels of plasma costicosterone than
SC mice (Table 3).
OGTT and IPITT
In the OGTT, the plasma glucose increased to a maximum
after 15 min of oral administration of glucose in both
groups, but this maximum was higher in HFC mice than in
SC mice (p<0.0001). The time-course of glucose clearance
in HFC mice was delayed compared to SC mice, remaining
elevated for 120 min (p<0.001) after glucose administration,
qualifying for characterization as glucose intolerance (Fig. 4).
The IPITT demonstrated a quick decline in plasma
glucose after 15 min of insulin administration in both groups,
but plasma glucose remained higher in HFC mice than in SC
mice (p<0.0001) at all time-points up to 120 min (Fig. 5),
characterizing the HFC mice as insulin resistant.
Structure of liver and pancreas
Liver was heavier (+25%, p = 0.03) and showed macro-
and microvesicular steatosis in HFD fed mice. Pancreas
was also heavier (+19%, p = 0.03) and had greater ectopic
fat deposition within pancreatic tissue, characterized by
intralobular and interlobular fatty deposition in HFC mice
compared to SC mice (Fig. 6).
The HFC mice showed larger pancreatic islets (islet
diameter varied from 115.2 ± 4.2 μm in SC mice to 151.3 ±
5.3 μm in HFC mice, +30%, p<0.01), and significantly
greater alpha and beta-cell immune-densities than SC mice
(Fig. 7, 8). As usual, positive immunostaining for glucagon
(alpha-cells) was found primarily at the islet periphery
(Fig. 7), while immunostaining for insulin (beta-cells) was
found primarily at the islet central zone (Fig. 8).
Discussion
This study demonstrates that adult C57BL/6 mice fed a
high-fat diet (60% fat) developed glucose intolerance,
insulin resistance and hepatopancreatic structural alterations
characterized by macro- and micro-steatosis, islet hyper-
trophy and increased alpha and beta-cell immune-densities,
beyond that expected from simply having increased body
biometry and fat storage. We also observed dyslipidemia
and expected high HDL-c levels in C57BL/6 mice [22], with
altered high plasma levels of ALT, AST and ALK. Plasma
glucose, insulin and costicosterone were also enhanced by
HFD administration, characterizing insulin resistance in the
animals.
Pancreatic ectopic fat accumulation in the interlobular
Fig. 2. Fat pads. Abdominal ventral view of dissected mice
showing the fat pads (bar = 2.5 mm): Retroperitoneal fat
pads: (a) SC group, the kidneys (white open arrows) are
surrounded by small fat pads extending until the urinary
bladder (black open arrow); (b) HFC group, the fat pads
(asterisks) are greater than in SC group, covering partial-
ly the kidneys. Epididymal fat pads: (c) SC group—they
cover up the inferior abdominal cavity but are much
more developed in HFC group (d) (arrows). Photomicro-
graphs of adipocytes (hematoxylin and eosin stain—
bar = 60 μm). (e) shows typical epididymal fat adipo-
cytes from lean mice fed SC and (f) shows adipocytes
for the HFC group, with greater diameter.Experimental Model of Metabolic Syndrome
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space (around the great vessels and ducts) and in the intral-
obular space (within the exocrine pancreas) was observed
after chronic HFD intake, suggesting NAFPD, which may
result in chronic pancreatitis. This observation is important
because experimental evidence supports the notion that
high-fat intake can induce hyperlipidemia and lead to
pancreatic endocrine and exocrine alterations [23], with
increased pancreatic FFA, lipid peroxidation and collagen
synthesis by activated pancreatic stellate cells [24], and
histopathological alterations resulting from an acute inflam-
matory response in the early stages of secondary pancreatic
acinar cell atrophy and fibrosis [11, 25].
Fatty acid intake displays time-dependent and deposit-
specific effects in mice [26]. In addition, it impairs the
regulation of pancreatic beta-cell cAMP production, a
signaling pathway important for adequate islet adaptation
to a perturbed metabolic environment. Normally this process
is protective against the development of glucose intolerance
and insulin resistance [12, 27]. C57BL/6 mice responded to
oversupply of dietary fat with adipose tissue remodeling,
through adipocyte hyperplasia and hypertrophy in agree-
ment with a previous report [28]. This is an important issue
because adipose tissue expresses various secretory proteins,
including leptin, TNF-alpha and adiponectin, which may
be involved in the regulation of energy expenditure, lipid
metabolism and insulin resistance [29].
Fig. 3. Feed efficiency. Feed efficiency (values are means) measured in standard chow (SC) group and in very high-fat chow (HFC)
group. The areas under the curve (AUC) show the differences between the groups. Values are mean ± SEM, n = 10/group.
Table 3. Blood biochemistry
1fasting insulin concentration (pmol/L) × fasting glucose concentration (mmol/L)/22.5
Values are mean ± SEM; n of 5–7 mice/group. LDL-c, low-density lipoprotein-cholesterol; HDL-c,
high-density lipoprotein-cholesterol; AST, aspartate aminotransferase; ALK, alkaline phosphatase;
ALT, alanine aminotransferase; SC, standard chow; HFC, high-fat chow.
Parameter
Groups SC vs HFC
SC HFC p
Glucose, mmol/L 8.3 ± 0.3 9.8 ± 0.4 0.01
Insulin, pmol/L 120.8 ± 1.1 219.8 ± 38.7 0.02
HOMA-IR index1 44.6 ± 5.3 95.7 ± 10.2 <0.001
Costicosterone (ng/mL) 68.7 ± 14.0 148.4 ± 30.6 0.03
Cholesterol, mg/dl 95.7 ± 3.5 104.0 ± 4.3 ns
LDL-c, mg/dl 41.8 ± 3.5 54.0 ± 2.5 0.02
HDL-c, mg/dl 54.0 ± 1.5 63.0 ± 2.2 0.002
Triglycerides, mg/dl 23.9 ± 2.6 43.9 ± 4.0 <0.001
AST, UI/l 245.2 ± 16.2 321.4 ± 6.2 <0.001
ALP, UI/l 47.4 ± 5.2 67.4 ± 4.6 0.01
ALK, UI/l 37.5 ± 5.7 76.0 ± 6.2 <0.001J.C. Fraulob et al.
J. Clin. Biochem. Nutr.
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Plasma adiponectin levels decrease during obesity, and
are negatively associated with plasma insulin, positively
associated with plasma triglycerides, and correlate with
increases in HOMA-IR [6]. Low levels of adiponectin
decrease fatty acid oxidation in the muscle, and this effect
is mediated by the interaction with muscle and hepatic
receptors through activation of AMP kinase, the cellular
“fuel gauge”, which, in turn, inhibits acetyl CoA carboxylase
and increases fatty acid beta-oxidation [30]. Additionally,
decreased adiponectin levels have been implicated in the
development of steatosis in mouse models of obesity and
lipodystrophy [31].
The HOMA-IR index is associated with myocardial
ischemia, independent of established risk factors [32].
Severe insulin resistance may impair glucose-stimulated
insulin secretion, thereby undermining beta-cell compensa-
tion and leading to hyperglycemia. Moreover, because
insulin stores are intact, the secretory defects reflect an
Fig. 4. Oral glucose tolerance test. Oral glucose tolerance test curve at 14th week. The areas under the curve show significant differ-
ences between the standard chow (SC) group and the very high-fat chow (HFC) group. Values are mean ± SEM, n = 5/group.
*p<0.05, different from HFC Group.
Fig. 5. Intraperitoneal insulin tolerance test. Intraperitoneal insulin tolerance test curve at 15th week. The areas under the curve show
significant differences between the standard chow (SC) group and the very high-fat chow (HFC) group. Values are
mean ± SEM, n = 5/group. *p<0.05, different from HFC Group.Experimental Model of Metabolic Syndrome
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early stage of beta-cell dysfunction [33]. The mice fed
HFD clearly displayed an elevated HOMA-IR index that is
compatible with the presence of insulin resistance in these
animals. One mechanism by which dietary overload of
lipids appears to lead to the development of insulin resis-
tance and T2D in C57BL/6J mice is by an increased satura-
tion of phospholipids of the mitochondrial membrane, leading
to decreased mitochondrial function [34]. In addition, the
failure of islet beta-cells to compensate for impaired insulin-
stimulated glucose disposal is one of the main mechanisms
underlying the onset of hyperglycemia and overt T2D [35].
The fatty liver is insulin resistant [36]. Liver fat is highly
and linearly correlated with all components of the MetS,
independent of obesity [2]. Therefore, NAFLD is emerging
as component of the MetS [9, 37]. NAFLD markers ALT
and AST predict MetS independently of potential con-
founding variables [38]. Serum ALT elevations have been
used as a surrogate biomarker for NAFLD and steato-
hepatitis in the clinical setting. ALT activity is normally
present at low levels in the circulation of standard chow
fed mice. In high fat/cholesterol fed mice, the incidence and
severity of elevated plasma ALT levels increased signifi-
cantly as a function of the time the animals were maintained
on this diet [22, 39]. Clinical evidence demonstrates that
fatty pancreas is associated with higher levels for visceral
fat, AST, ALT, total cholesterol, triglyceride, insulin, and the
HOMA-IR [40]. Likewise, C57BL/6 mice fed a HFD
showed elevated ALT, AST and ALK plasma concentrations
indicating alteration of the hepatic and pancreatic function.
Chronic stress is associated with derangement of meta-
bolic homeostasis, a process that contributes to the clinical
presentation of visceral obesity, T2D, atherosclerosis and
MetS. Obesity constitutes a chronic stressful state that may
cause hypothalamic-pituitary-adrenal (HPA) axis dysfunc-
tion [41]. Basal HPA axis activity and expression of its
central regulatory markers are age-dependent in mice [42].
Fig. 6. Photomicrographs of liver and pancreas. Photomicrographs of liver and pancreas (hematoxylin and eosin stain): (a) typical liver
of a lean mice fed SC and (b) liver of high-fat fed mice with macro- and microvesicular steatosis (arrows); (c) typical pancreas
of a lean mice fed SC and (d) pancreas of high-fat fed mice showing intracellular lipid vesicles in acinar cells (arrows); (e)
adipose infiltration in pancreas of high-fat fed mice (black arrow) and (f) ectopic deposition of the interlobular fat of high-fat
fed mice (black arrow).J.C. Fraulob et al.
J. Clin. Biochem. Nutr.
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Furthermore, dietary fat intake acts as a background form of
chronic stress, elevating basal corticosterone levels and
enhancing HPA response to stress [43]. The combination of
stress and MetS increases the risk of cardiovascular disease
[1]. In the present study, in spite of having carefully con-
trolled for effects of age, mice fed HFD had significantly
higher levels of plasma costicosterone than control mice.
This corticosterone index could be correlated with an
increase in both obesity and symptoms of metabolic syn-
drome [43].
By feeding mice a HFD, this study has arrived at several
striking observations. In addition to observing the develop-
ment of insulin resistance in mice fed a chronic HFD, we
observed structural alterations such as liver macro and
micro steatosis, larger pancreatic islets, greater alpha and
beta-cell immuno-densities and ectopic fat deposition within
pancreatic tissue. These observations seem to be alterations
due to oversupply of lipids and are independent of the aging
process in mice. Increased islet size and pancreatic insulin
content in old non-obese (21–25-month-old) C57BL/6J
male mice have already been reported [44]. A nearly twofold
increase in islet size was correlated with a twofold increase
of glucose-stimulated insulin secretion from perifused islets
from 25-month-old males compared with 5-month-old
males. Thus, the findings that glucose tolerance did not
deteriorate with age, coupled with the lack of evidence for
impaired beta-cell responsiveness to glucose in old males,
suggest that the deterioration in glucose homeostasis seen in
this study is not an inevitable consequence of aging in mice.
We found greater alpha and beta-cell immuno densities in
mice fed HFD, but no differences in the islet distribution
of these cells. Adeghate and co-workers found a similar
percentage of insulin-positive (around 80%) and glucagon-
positive cells (around 10%) in C57BL/6 mice fed fat-
enriched diet compared to mice fed control diet [45]. It is
also possible to demonstrate this effect by analyzing the
density of immunolabeled cells, as measured by image
analysis. By examining this in both groups, significant
variations in densities of both cell types were found.
Insulin and glucagon are all secreted from the endocrine
Fig. 7. Pancreatic islet alpha-cell. The pancreatic islet alpha-cell
volume densities in the standard chow (SC) group and in
the very high-fat chow (HFC) group were measured by
image analysis. It was significantly greater in the HFC
group. Photomicrographs under de column bars show
typical islets of the two groups with positive stain for
glucagon (same magnification, bar = 40 μm). Values are
mean ± SEM, n = 10/group.
Fig. 8. Pancreatic islet beta-cell. The pancreatic islet beta-cell
volume densities in the standard chow (SC) group and in
the very high-fat chow (HFC) group were measured by
image analysis. It was significantly greater in the HFC
group. Photomicrographs under de column bars show
typical islets of the two groups with positive stain for
insulin (same magnification, bar = 40 μm). Values are
mean ± SEM, n = 10/group.Experimental Model of Metabolic Syndrome
Vol. 46, No. 3, 2010
221
pancreas, and both participate in the regulation of energy
homeostasis. Increased expression of glucagon in the islets
is proportionally related to an increase of its concentration
in the blood [46–47]. By using a differential energetic base
in age matched animals fed a diet higher in fat and carbo-
hydrates (C57BL/6 mice fed a high-fat-high-sucrose diet,
consisting of 44% carbohydrates with 16% sucrose and 42%
fat), had increased pancreatic insulin and lower glucagon
content [11, 13]. Thus, pancreatic glucagon content appears
to be influenced by food composition [48].
The liver is also simultaneously influenced by competing
signals with regard to glucose secretion, since glucagon both
stimulates insulin secretion and increases hepatic glucose
output. Glucagon acts mainly in the liver, where it increases
glucose production, while generating signals to reduce
energy intake. Insulin acts directly at the liver to suppress the
synthesis and secretion of glucose, and some plasma insulin
is transported into the brain where it provides an important
and indeed necessary input for the appropriate regulation of
both stored energy and glucose secretion by the liver [49].
This analysis is important because the pancreatic beta-cell
function is regulated by insulin signaling pathways. Insulin
receptor substrate 2-dependent signaling in pancreatic islets
is required not only for the maintenance of normal alpha
and beta-cell mass, but is also involved in the regulation of
insulin secretion [50, 51].
Currently, many studies have reported that C57BL/6 mice
develop obesity, insulin resistant, diabetes mellitus, hyper-
triglyceridemia [11,  13] and advanced fatty liver disease
when fed a high-fat diet, mimicking human metabolic
syndrome. Compared with other animal models, such as
Zucker obese rats, ob/ob or db/db mice or other gene
deletion animal models, these HFD mice more closely
resemble human obesity, serving as a model of exogenous
obesity, which arises via a higher dietary caloric intake
(fat overload) [52].
We now report, using stereological methods, that the
pancreas of high-fat fed mice develops intracellular lipid
vesicles in acinar cells, adipose infiltration and ectopic
deposition of the interlobular fat, in addition to macro- and
microvesicular steatosis in liver.
The HFD mouse model may promote a better experi-
mental system in which to investigate MetS, by providing a
model to examine interventions that prevent progression of
fatty liver and fatty pancreas disease and to correlate the
degree of liver and pancreatic steatosis with metabolic
syndrome.
In conclusion, C57BL/6 mice fed a high fat diet develop
features of both non-alcoholic fatty liver disease and non-
alcoholic fatty pancreatic disease, a condition that is closely
related to MetS. Ectopic accumulation of fat in liver and
pancreas is a well-known symptom of MetS. However, only
recently has the importance of fat accumulation in these
tissues been highlighted. Therefore, the HFD animal model
could help us to better understand the target organ alterations
associated with metabolic syndrome and engender the possi-
bility of developing novel treatments.
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